Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials

BR is also an effective and safe regimen for untreated CLL patients, outside of controlled clinical trials.